Qualitest Pharmaceuticals, an operating company of Endo Health Solutions Inc. (ENDP), said Monday it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck & Co. Inc. (MRK) U.S. market exclusivity.
Qualitest said it will begin shipping the product immediately. Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis.
The total combined sales for Montelukast Sodium Tablets and Chewables in the U.S. for the 12 months ending June 30, 2012, were about $4.9 billion, according to IMS Health
For comments and feedback: editorial@rttnews.com